OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis

This study evaluated the effects of combining an OX40 agonistic antibody (aOX40) with a cell vaccine targeting HER2/neu, called “Triplex”. Such HER2/neu cell vaccine included two biological adjuvants (interleukin 12 (IL12) and allogeneic histocompatibility antigens) and was previously found able to...

Full description

Bibliographic Details
Main Authors: Patrizia Nanni, Carla De Giovanni, Alessia Burocchi, Giordano Nicoletti, Lorena Landuzzi, Arianna Palladini, Marianna Lucia Ianzano, Ivano Arioli, Mario P. Colombo, Pier-Luigi Lollini
Format: Article
Language:English
Published: Taylor & Francis Group 2018-08-01
Series:OncoImmunology
Subjects:
cancer vaccine
her2/neu
immunoprevention
mammary cancer
ox40
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1465164

Internet

http://dx.doi.org/10.1080/2162402X.2018.1465164

Similar Items